Keel Point’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Keel Point’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,418	Closed	-$3.44M	–	308
2020 Q4	$3.44M	Buy	+24,418	New	+$3.13M	0.31%	50
2018 Q3	–	Sell	-70,855	Closed	-$6.75M	–	203
2018 Q2	$6.75M	Buy	+70,855	New	+$6.51M	0.9%	23

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Keel Point's XBI Position: Q1 2021 in Review

Keel Point sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2021, closing a stake of 24,418 shares — an estimated $3.44M sold.

Keel Point first reported a position in XBI in Q2 2018 and held it in 2 quarters. The position peaked at $6.75M in Q2 2018. 643 funds tracked by Wall St. Rank hold XBI as of Q1 2021.

Keel Point reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2021 after selling out during the quarter.
Keel Point sold 24,418 State Street SPDR S&P Biotech ETF shares in Q1 2021, an estimated $3.44M.
Keel Point first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and held it in 2 quarters.
Keel Point's State Street SPDR S&P Biotech ETF position peaked at $6.75M in Q2 2018.
643 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2021.

Based on Keel Point's 13F filing for Q1 2021, filed 17 May 2021.